View Clinical Trial (Medical Research Study)

Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot - NCT00126334-20010A(Clinical Trial 126317)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Washington
State:  
DC
Zip Code: 20010
Conditions: Myocardial Infarction - Anemia
Purpose: The purpose of this trial is to determine whether a conservative or a liberal blood transfusion strategy is better for patients with a heart attack and a low blood count.
Study summary: The current standard of care for patients with heart attacks is to transfuse red blood cells when the hematocrit (red blood cell count) drops below 30 percent. However, there is little scientific basis for this current standard, and recent research has demonstrated that it is safe to allow the hematocrit (red blood cell count) to drop significantly lower in severely ill medical patients and in patients with heart disease undergoing major surgery. The investigators therefore propose this pilot trial to begin to determine whether or not it is safe to apply a more conservative blood transfusion strategy to patients with heart attacks. In this study, patients who are within 72 hours of the onset of a heart attack and who are anemic (have a low red blood cell count) will be randomly assigned to one of two transfusion strategies while they are in the hospital: a liberal strategy of transfusing blood when the hematocrit falls below 30 percent (the current standard) or a conservative strategy of transfusing blood only when the hematocrit falls below 24 percent. It will then be determined which group fares better over the next 30 days. The plan is to enroll 92 patients in this pilot trial in order to allow the researchers to plan for a much larger, definitive trial of this important question. It is anticipated that the conservative transfusion strategy will be similar to the standard (liberal) strategy in terms of patient outcomes.
Criteria: Inclusion Criteria: All of the following must be present: - Acute myocardial infarction with presentation within 72 hours of randomization (acute myocardial infarction is defined as ischemic-type chest discomfort lasting at least 30 minutes associated with creatinine kinase MB (CKMB) or troponin >upper limit of normal [ULN]) - Admission to CCU - Hematocrit .30 or less - Written, informed consent Exclusion Criteria: - Inability or unwillingness to receive red cell transfusions - Active bleeding (overt blood loss accompanied by a decrease in hematocrit of at least 5% in the preceding 12 hours) - Receipt of red cell transfusion within 7 days of randomization - Prior severe transfusion reaction - Pregnancy - Imminent death - Decision to provide limited care - Age <21 - Participation in another clinical trial in which blood transfusion is a requirement or a component of a primary or secondary endpoint - Previous participation in the CRIT Pilot
Study is available at: Washington Hospital Center
Washington, DC 20010
United States

Primary Contact:
Howard A Cooper, MD
Email: howard.a.cooper@medstar.net
Phone: 202-877-6348

Secondary Contact:
Howard A Cooper, M.D.
Email: howard.a.cooper@medstar.net
Phone: 202-877-6348
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 21, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.